+279.2%
ASX vs MRNA
+159.5%
+119.6%
-40.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.2% | +1.3% | -7.5% | -6.3% |
| 7D | -16.0% | -13.8% | -2.1% | -15.4% |
| 30D | -25.2% | -17.7% | -7.6% | -24.4% |
| 3M | -14.5% | +14.3% | -28.8% | -15.1% |
| 6M | -0.3% | +336.0% | -336.3% | -14.2% |
| YTD | +91.3% | +575.9% | -484.6% | +49.1% |
| 1Y | +118.9% | +724.4% | -605.5% | +63.4% |
| All | +279.2% | +159.5% | +119.6% | +225.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling